StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
O0C.F$2.06+0.00%
Fair $2.06+0.0%

O0C.F

Med Life S.A.

Healthcare / Medical Care FacilitiesFrankfurt

$2.06

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.06Fund rank 21/100 · Data gapFallback financials|
SA 41/C
F-Score: 6/9
High Debt

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 12%

FCF escenarios

weak_data · normalized FCF $15.3M · quality 21.7/100

Data gap 21/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 27/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

41/100

C

Piotroski

6/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 1unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. Debt-to-Equity ratio is 4.04, above the 2.0 threshold
Thesis & Journal · O0C.FLocal privado en este navegador · Med Life S.A.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.1B

P/E

42.7x

↑

EV/EBITDA

7.0x

↓

ROE

5.9%

↑

Gross Margin

81.6%

↑

Debt/Equity

4.04

↑
52-Week Range$2
$1$3

TradingView lightweight chart

O0C.F price, volumen y niveles de valoración

Último $2.055Periodo +76.9%
Fair value: $2.055

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2021–2024 · 3 años de histórico normalizado

Revenue CAGR

+23.9%

FCF CAGR

-40.0%

FCF margin

1.0%

FCF / Net income

1.10x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $2.72B · net income $25.5M · FCF $28.1M

2021-FY → 2024-FY

Gross margin

81.6%-2.0% pts

Operating margin

5.6%-6.8% pts

Net margin

0.9%-6.2% pts

FCF margin

1.0%-8.1% pts
MetricTTM
2024
2023
2022
2021
Income Statement
Revenue$2.72B$2.72B$2.21B$1.80B$1.43B
Net Income$25.5M$25.5M$3.7M$32.2M$102.6M
EBITDA$387.6M$387.6M$278.0M$236.3M$270.8M
EPS0.050.050.010.060.19
Gross Margin81.6%81.6%82.4%82.7%83.6%
Operating Margin5.6%5.6%4.3%5.5%12.4%
Net Margin0.9%0.9%0.2%1.8%7.2%
Balance Sheet
Debt/Equity4.044.043.762.852.15
Current Ratio0.790.79———
Cash Flow
Free Cash Flow$28.1M$28.1M$-36.4M$15.3M$130.5M
Returns
ROE5.9%5.9%0.9%7.7%30.3%
Valuation
P/E42.7242.72———
EV/EBITDA7.047.04———
P/B2.522.52———
Growth & Yield
Revenue Growth22.8%22.8%23.1%25.8%—
EPS Growth587.1%587.1%-88.5%-68.3%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

55.9%

muy exigente

EPS terminal req.

$0.18

Spread vs growth

531.2%

5Y implied EPS CAGR

35.6%

muy exigente

EPS terminal req.

$0.22

Spread vs growth

551.5%

10Y implied EPS CAGR

22.1%

exigente

EPS terminal req.

$0.36

Spread vs growth

565.0%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +62.6%

Total return

+62.6%

Start / end P/E

180.5x → 42.7x

EPS bridge

0.01 → 0.05

Residual

-448.2%

EPS growth+587.1%
Multiple rerating-76.3%
Dividend+0.0%
Residual / FX / buybacks / cross-term-448.2%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.